'Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Ca

An 'innovative' study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved 'unprecedented' pathologic responses, with no recurrences.

Related Keywords

Paris , France General , France , Netherlands , United Kingdom , Valencia , Carabobo , Venezuela , Spain , London , City Of , Amsterdam , Noord Holland , James Larkin , Myriam Chalabi , Netherlands Cancer Institute , European Society For Medical Oncology , University Of Valencia , European Society , Medical Oncology , Annuak Meeting , New Results , Royal Marsden , Colorectal Cancer , Cancer , Alignant Neoplasia , Arcinoma , Colon Cancer , Alignant Colon Neoplasm , Tumor , Chemotherapy , Malignant Rectal Neoplasm , Rectal Cancer , Ancer Rectal , Surgery , Biologic Therapy , Biopsy , Immunotherapy , Metastasis , Colonoscopy , Neoadjuvant , Presection , Disease Recurrence ,